Journal Reviews

Lucentis for pseudophakic CMO

1 October 2015 | | Retina / Uvea / Vitreous | Cataract, Irvine-Gass syndrome, cystoid macular edema, phacoemulsification, ranibizumab

Pseudophakic cystoid macular oedema (CMO) develops angiographically in up to 20-30% after uneventful phacoemulsification. This study aimed to evaluate the potential efficacy and safety of intravitreal ranibizumab in patients with pseudophakic CMO after cataract surgery. Seven eyes were included in...